Prognostic Value of Elevated Troponins in Critical Illness Study: A Pilot Study
PRO-TROPICS
2 other identifiers
observational
251
0 countries
N/A
Brief Summary
Troponins are sensitive and specific markers of cardiac injury. Critically ill patients frequently have elevated troponins. In this population, distinguishing patients with elevated troponins from those with myocardial infarction is difficult. However, troponin elevations on their own seem to be associated with an increased risk of death. The optimal treatment of patients with type 2 myocardial infarction or non ischemia related troponin elevations during critical illness is unclear. There are no trials in the ICU setting to guide management. This study is a 1-month pilot cohort study of troponin screening in 4 Ontario intensive care units. The objective of this pilot study is to evaluate the ability to perform a larger study, which will determine the prevalence, incidence and risk factors for elevated troponin values, how patients with elevated troponin values are treated as a baseline, and the incidence of myocardial infarction in critically ill patients. Knowing the prognostic impact of these conditions and understanding current management will thereafter guide researchers and clinicians on the importance of carefully evaluating potential risk-modifying therapies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Nov 2014
Shorter than P25 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
November 1, 2014
CompletedFirst Submitted
Initial submission to the registry
November 5, 2014
CompletedFirst Posted
Study publicly available on registry
November 7, 2014
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 15, 2015
CompletedStudy Completion
Last participant's last visit for all outcomes
March 30, 2015
CompletedNovember 1, 2017
October 1, 2017
4 months
November 5, 2014
October 30, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (3)
Recruitment rate
Feasibility outcome
1 month
Data collection time per patient
Feasibility outcome
3 months
rate of successful deferred informed consent definition
Feasibility outcome
1 month
Secondary Outcomes (3)
All-cause in-hospital mortality
3 months
Troponin elevations
3 months
Myocardial infarction
3 months
Eligibility Criteria
Critically ill patients
You may qualify if:
- All adult patients admitted to the participating ICUs of study sites during the study enrollment period will be eligible.
You may not qualify if:
- Patients who are admitted and die or are discharged within 12 hours
- Patients re-admitted to ICU during the index ICU enrolment month
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Biospecimen
2 cryovials
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 5, 2014
First Posted
November 7, 2014
Study Start
November 1, 2014
Primary Completion
March 15, 2015
Study Completion
March 30, 2015
Last Updated
November 1, 2017
Record last verified: 2017-10